mRNA-encoded self-assembling enveloped virus-like particles presenting SARS-CoV-2 spike protein enhance immunity and may provide better protection against viral variants.
Researchers continue to debate whether US President Abraham Lincoln was coming down with smallpox as he delivered his famous Gettysburg Address, and if he had been immunized.
Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.
Jaclyn Winter and Shiladitya DasSarma will discuss how they harness the unique biology of extremophiles for the discovery and development of new therapeutics.
James R. Heath, PhD, President of the Institute for Systems Biology will discuss key single-cell learnings and applications from the large Seattle-based academic pharmaceutical consortium committed to defining molecular mechanisms of SARS-CoV-2 infection and identifying potential prognostic immune biomarkers. Stacey Willard, PhD, from IsoPlexis will discuss how functional phenotyping individual immune cells using IsoPlexis technology edges researchers closer to predicting the risk for severe disease.